Gastroösophageale Refluxkrankheit – Update 2018

Vor einer Dekade erschien der Beitrag über die gastroösophageale Refluxkrankheit in diesem Journal [1] – somit ist es Zeit für eine kritische Bestandsaufnahme und Überprüfung der Empfehlungen. Mittlerweile erschienen zudem die überarbeitete Leitlinie der DGVS [2] und eine Übersicht zu aktuellen Kontroversen der Refluxtherapie [3]. Nachfolgend wird daher der aktuelle Wissensstand zu Diagnostik, Therapie und aufkommenden Entwicklungen dargestellt.

Schlüsselwörter

Funktionsdiagnostik - Acid Pocket - extraösophageale Manifestationen - Barrett-Ösophagus - Protonenpumpeninhibitoren

• Literatur

• 1 Koop H, Benter T. Gastroösophageale Refluxkrankheit – Klinik, Diagnostik und Therapie. Gastroenterologie up2date 2008; 4: 117-132
• 2 Koop H, Fuchs KH, Labenz J. et al. S2k-Leitlinie: Gastroösophageale Refluxkrankheit unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten. AWMF Register Nr. 021-013. Z Gastroenterol 2014; 52: 1299-1346
• 3 Labenz J, Koop H. Gastroösophageale Refluxkrankheit – was tun, wenn PPI nicht ausreichend wirksam, verträglich oder erwünscht sind?. Dtsch Med Wschr 2017; 152: 356-366
• 4 Vakil N, van Zanten SV, Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920
• 5 Yadlapati R, Tye M, Keefer L. et al. Psychological distress and quality of life impairment are associated with symptom severity in PPI non-responders with normal impedance-pH profiles. Am J Gastroenterol 2017;
• 6 Weijenborg PW, Bredenoord AJ. How reflux causes symptoms: reflux perception in gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol 2013; 27: 353-364
• 7 Fletcher J, Wirz A, Young J. et al. Unbuffered highly acid gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-783
• 8 Clarke AT, Wirz AA, Seenan JP. et al. Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic. Gut 2009; 58: 904-909
• 9 Beaumont H, Bennink RJ, de Jong J. et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441-451
• 10 Kahrilas PJ, McColl K, Fox M. et al. The acid pocket: a target for treatment in reflux disease?. Am J Gastroenterol 2013; 108: 1058-1064
• 11 Herregods TV, Bredenoort AJ, Smout AJ. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil 2015; 27: 1202-1213
• 12 Frieling T, Bergoldt G, Allescher HD. et al. Brustschmerz – nicht immer das Herz. Klinische Bedeutung gastrointestinaler Erkrankungen beim nicht-kardialen Thoraxschmerz. Z Gastroenterol 2015; 53: 120-124
• 13 Labenz J, Labenz C. Gastroenterologische Erkrankungen als Auslöser von Thoraxschmerz. Internist 2017; 58: 29-38
• 14 Ronkainen J, Talley NJ, Storskrubb T. et al. Erosive esophagitis is a risk factor for Barrettʼs esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol 2011; 106: 1946-1952
• 15 Leodolter A, Nocon M, Vieth M. et al. Progression of specialized intestinal metaplasia at the cardia to macroscopically evident Barrettʼs esophagus: an entity of concern in the ProGERD study. Scand J Gastroenterol 2012; 47: 1429-1435
• 16 Fuchs KH, Musial F, Ulbricht F. et al. Foregut symptoms, somatoform tendencies, and the selection of patients for antireflux surgery. Dis Esophagus 2017; 30: 1-10
• 17 Cremonini F, Wise J, Moayyedi P. et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100: 1226-1232
• 18 Vakil N, Vieth M, Wernersson B. et al. Diagnosis of oesophageal reflux disease is enhanced by adding oesophageal histology and exclusing epigastric pain. Aliment Pharmacol Ther 2017; 45: 1350-1357
• 19 Roman S, Gyawali CP, Savarino E. et al. Ambulatory reflux monitoring for diagnosis of gastroesophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017; 29: 1-15
• 20 Kahrilas PJ, Jonsson A, Denison H. et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 612-619
• 21 Eusebi LH, Ratnakumaran R, Bazzoli F, Ford AC. Prevalence of dyspepsia in individuals with gastroesophageal reflux-type symptoms in the community: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 39-48
• 22 El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-737
• 23 Ichikawa H, Sugimoto M, Sugimoto K. et al. Rapid metabolizer genotype of CYP 2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol 2016; 31: 716-726
• 24 Kirchheiner J, Glatt S, Fuhr U. et al. Relative potencies of proton pump inhibitors – comparison of effects on intragastric pH. Eur J Pharmacol 2009; 65: 19-31
• 25 Koop H. Verordnungspraxis und Risiken von Protonenpumpenblockern – Fiktion und Fakten. Z Gastroenterol 2018;
• 26 Coyle C, Crawford G, Wilkinson J. et al. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther 2017; 45: 1524-1533
• 27 Kahrilas PJ, Boeckxstaens G. Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients?. Gut 2012; 61: 1501-1509
• 28 Yadlapati R, Tye M, Roman S. et al. Postprandial high-resolution impedance manometry identifies mechanisms of nonresponse to proton pump inhibitors. Clin Gastroenterol Hepatol 2018; 16: 211-218
• 29 Du X, Hu Z, Yan C. et al. A meta-analysis of long follow-up outcomes of laparoscopic Nissen (total) versus Toupet (270°) fundoplication for gastro-esophageal reflux disease based on randomized controlled trials in adults. BMC Gastroenterol 2016; 16: 88
• 30 de Bortoli N, Martinucci I, Savarino E. et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?. Neurogastroenterol Motil 2014; 26: 28-35
• 31 Lundell L, Bell M, Ruth M. Systematic review: laparoscopic fundoplication for gastroesophageal reflux disease in partial responders to proton pump inhibitors. World J Gastroenterol 2014; 21: 804-813
• 32 Kappelle WF, Bredenoord AJ, Conchillo JM. et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial. Aliment Pharmacol Ther 2015; 42: 614-625
• 33 Rodriguez L, Rodriguez P, Gomez B. et al. Two-year results of an intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease. Surgery 2015; 157: 556-567
• 34 Skubleny D, Switzer NJ, Dang J. et al. Linx^® magnetic sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc 2017; 31: 3078-3084
• 35 Jaspersen D, Labenz J, Willich SN. et al. Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease: a prospective follow-up analysis based on the PROGERD study. Dig Liver Dis 2006; 38: 233-238
• 36 Gibson PG, Vertigan AE. Management of chronic refractory cough. BMJ 2015; 351: h5590
• 37 Chang AB, Lasserson TJ, Gaffney J. et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2006; (04) CD004823
• 38 Qadeer MA, Phillips CO, Lopez AR. et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trial. Am J Gastroenterol 2006; 101: 2646-2654
• 39 American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360: 1487-1499
• 40 Smith JA, Houghton LA. The oesophagus and cough: laryngo-pharyngeal reflux, microaspiration and vagal reflexes. Cough 2013; 9: 12
• 41 Herregods TVK, Pauwels A, Jafari J. et al. Determinants of reflux-induced chronic cough. Gut 2017; 66: 2057-2062
• 42 Morice AH. The cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lung 2010; 188 (Suppl. 01) S87-S91
• 43 Abdulqawi R, Dockry R, Holt K. et al. P2X3 receptor antagonist (AF219) in refractory chronic cough: a randomized, double-blind, placebo-controlled phase 2 study. Lancet 2015; 385: 1198-1205
• 44 Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009; 22: 65-70
• 45 Thosani N, Abu Dayyeh BK, Sharma P. et al. ASGE Technical Committee systematic review and meta-analysis assessing the ASGE Preservation and Incorporation of valuable Endoscopic Innovations thresholds for adopting real-time imaging-assisted endoscopic target biopsy during endoscopic surveillance of Barrettʼs esophagus. Gastrointest Endosc 2016; 83: 684-698.e7
• 46 Pohl H, Aschenbeck J, Drossel R. et al. Endoscopy in Barrettʼs oesophagus: adherance to standards and neoplasia detection in the community practice versus hospital setting. J Intern Med 2008; 264: 370-378
• 47 Cotton CC, Wolf WA, Overholt BF. et al. Late recurrence of Barrettʼs esophagus after complete eradication if intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology 2017; 153: 681-688
• 48 Thota PN, Vennalaganti P, Vennalaganti S. et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients with Barrettʼs esophagus less than 1 cm (irregular Z-line) within 5 years of index endoscopy. Gastroenterology 2017; 152: 987-992
• 49 Pohl H, Pech O, Arash H. et al. Length of Barrettʼs oesophagus and cancer risk: implications for a large sample of patients with early oesophageal adenocarcinoma. Gut 2016; 65: 196-201